Sepsis is a life-threatening syndrome with disturbed host responses to severe infections, accounting for the majority of death in hospitalized patients. However, effective medicines are currently scant in clinics due to the poor understanding of the exact underlying mechanism. We previously found that blocking caspase-11 pathway (human orthologs caspase-4/5) is effective to rescue coagulation-induced organ dysfunction and lethality in sepsis models. Herein, we screened our existing chemical pools established in our lab using bacterial outer membrane vesicle (OMV)-challenged macrophages, and found 7-(diethylamino)-1-hydroxy-phenothiazin-3-ylidene-diethylazanium chloride (PHZ-OH), a novel phenothiazinium-based derivative, was capable of robustly dampening caspase-11-dependent pyroptosis. The in-vitro study both in physics and physiology showed that PHZ-OH targeted AP2-associated protein kinase 1 (AAK1) and thus prevented AAK1-mediated LPS internalization for caspase-11 activation. By using a series of gene-modified mice, our in-vivo study further demonstrated that administration of PHZ-OH significantly protected mice against sepsis-associated coagulation, multiple organ dysfunction, and death. Besides, PHZ-OH showed additional protection on Nlpr3−/− and Casp1−/− mice but not on Casp11−/−, Casp1/11−/−, Msr1−/−, and AAK1 inhibitor-treated mice. These results suggest the critical role of AAK1 on caspase-11 signaling and may provide a new avenue that targeting AAK1-mediated LPS internalization would be a promising therapeutic strategy for sepsis. In particular, PHZ-OH may serve as a favorable molecule and an attractive scaffold in future medicine development for efficient treatment of bacterial sepsis.

**INTRODUCTION**

Sepsis, a syndrome with dysregulated host response to infection, is the leading cause of death worldwide [1, 2]. To date, clinical treatments of sepsis are mainly based on infection-prevention and life-supporting techniques, as efficient targeting medicines against sepsis are still scant due to the insufficient understanding of the explicit underlying mechanism. Therefore, development of novel therapeutic agents, especially those with favorable efficacy and explicit mechanism, are highly imperative in the treatment of sepsis.

Caspase-11 (human orthologs caspase-4 or caspase-5) is a pattern-recognition receptor (PRR) of innate immune system for the recognition of intracellular lipopolysaccharide (LPS) - the major pathogenic component of gram-negative bacteria [3–5]. We have previously demonstrated that caspase-11-mediated gasdermin D (GSDMD) pores magnify phosphatidylserine exposure of macrophages, thus enhancing the activity of tissue factor (TF) and subsequently promoting the coagulation cascades [6]. Coagulation is physiologically essential to trap invading microorganisms, thereby preventing microorganism diffusion and infection progression [7]. However, infection-induced sepsis often leads to excessive coagulation activation, which may result in life-threatening disseminated intravascular coagulation (DIC), and likely to induce multiple organ dysfunction and eventually death [2, 8, 9]. Our previous study showed that caspase-11 or GSDMD (the downstream) deficiency significantly attenuates LPS-induced DIC and subsequent death [6]. Also, we found that blocking type 1 IFNs pathway reduces hepatocyte-derived HMGB1, which dampens HMGB1-assistant LPS internalization and caspase-11-dependent DIC. [10]. Thus, inhibition of caspase-4/5/11 pathway would be a promising strategy to rescue coagulation syndrome and lethality in bacterial sepsis.

Clinical epidemiological studies have shown that gram-negative bacteria are the predominant pathogenic bacteria of sepsis-
induced DIC [11]. Outer membrane vesicle (OMV), a compartment commonly secreted from gram-negative bacteria, is capable of delivering LPS into the cytosol of host cells, and thus results in caspase-11 activation [12]. In this study, we established a cell-based high-throughput drug screening system by using OMV-stimulated mice peritoneal macrophages [13, 14], and identified a novel phenothiazinium-based derivative, 7-(diethy lamino)-1-hydroxy-pheno thiazin-3-ylidine-diethylazanium chloride (PHZ-OH), which significantly suppressed OMV-mediated caspase-11 activation. Of note, administration of PHZ-OH attenuated coagulation activation, multiple organ injury and death in both lethal bacterial sepsis and sterile endotoxia mia. The protective effects of PHZ-OH were mainly ascribed to blocking the AP2-associated protein kinase 1 (AAK1)-mediated endocytosis of LPS, thereby reducing the activation of caspase-11. Taken together, our findings suggest that pharmacologically targeting AAK1-mediated LPS internalization is a valuable therapeutic option for sepsis. PHZ-OH, a new and promising inhibitor of AAK1, may facilitate the future discovery of novel agents for efficient treatment of coagulation syndrome, organ dysfunction, and death in bacterial sepsis.

RESULTS
1-hydroxy phenothiazinium-based small molecule inhibits OMV-mediated caspase-11 signaling
To identify novel and efficient inhibitors of caspase-11 signaling, we screened our existing chemical pools established in our lab by using mice peritoneal macrophages under a challenge of bacterial outer membrane vesicle (OMV)-the major transporter of LPS into the cytosol for caspase-11 activation [12] (Fig. 1A). We found that PHZ-OH, with excellent physicochemical and pharmaceutical properties according to Lipinski, Hann, and Veber’s rules [15–17] (Fig. 1B, Scheme S1, and Figs. S1–S4), displayed significant inhibition on OMV-induced pyroptosis. Given that caspase-11 activation not only induces GSDMD-associated cell death and the release of inflammasome-independent interleukin-1α (IL-1α), but also triggers NLRP3 inflammasome and the mature and secretion of inflammasome-dependent IL-1β and IL-18 [18], we thus challenged WT, Casp11−/−, Gsdmd−/− and Nlpr3−/−deficient primary peritoneal macrophages with OMV or Escherichia coli to verify the involvement of caspase-11 signaling. It was found that OMV or E. coli-induced cell death and IL-1α/β secretion were largely reduced by deleting caspase-11 and GSDMD, whilst deficiency of NLRP3 only blocked the inflammasome-dependent IL-1β release but not cell death and IL-1α secretion (Figs. 1C and S5A), indicating the caspase-11-dependent cell killing and cytokine release. Moreover, PHZ-OH significantly inhibited the OMV- or E. coli-induced cell death and IL-1α secretion in WT and Nlpr3−/− but not Casp11−/− and Gsdmd−/−deficient macrophages, suggesting PHZ-OH is an inhibitor of caspase-11 signaling (Fig. 1C).

It has been recognized that the priming signal, commonly stimulated by toll-like receptors (TLRs), upregulates the expression of caspase-11 and thus facilitates caspase-11-dependent pyroptosis [3, 18]. To reveal if PHZ-OH exerts the inhibitory effect via inhibiting the priming signal, we treated macrophage with PHZ-OH after a priming of LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist) or Poly(I:C) (TLR3 agonist). It was found that priming of TLR agonists boosted the expression of caspase-11 but did not directly lead to cytotoxicity and IL-1 release until the challenge of OMV or E. coli (Figs. 1D and S5B). Meanwhile, treatment with PHZ-OH did not affect TLR-dependent caspase-11 expression but significantly attenuated OMV- or E. coli-induced cell death and IL-1α/β secretion (Figs. 1D and S5B). In addition, depletion of Myd88, the downstream of TLRs, almost completely blocked the release of TLR-related cytokines, tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) (Fig. S5C), and reduced the inflammatory pyroptosis in OMV-challenged macrophages (Fig. S5D), while additional treatment with PHZ-OH further promoted the reduction of pyroptosis at the basis of Myd88 deficiency (Fig. S5D). Moreover, TNFα and IL-6 were not significantly altered by the treatment of PHZ-OH (Figs. SSC and 1E). Western blots also showed that PHZ-OH significantly inhibited caspase-11-dependent GSDMD cleavage rather than the expression of caspase-11 and IL-1α/β (Fig. 1F). These results suggest that PHZ-OH exerts the inhibition on caspase-11 signaling independent of TLRs. Besides, we found an apparent dose-dependent activity of PHZ-OH on WT rather than Casp11−/−deficient macrophages challenged with OMV (Fig. 1G, H). To further confirm the activity on human source samples, we treated THP-1 cells with PHZ-OH and OMV using knocking down caspase-4 (human ortholog of caspase-11) as the negative control [19]. The results showed that PHZ-OH demonstrated similar dose-dependent inhibition effects on WT but not caspase-4 knockdown macrophages in terms of cell death and cytokine releases (Fig. 1I, J). Taken together, these results show that PHZ-OH could prevent OMV-mediated pyroptosis by selectively inhibiting caspase-4/5/11 pathway in vitro.

Administration of PHZ-OH alleviates organ dysfunction and lethality in septic mice
To investigate the potential effects of PHZ-OH on sepsis, WT and Casp11−/− mice were administered with saline or PHZ-OH prior to a challenge of cecal ligation and puncture (CLP, polymicrobial sepsis) or E. coli (Gram-negative sepsis). Similar to the deficiency of caspase-11, administration of PHZ-OH significantly improved the survival rate in WT bacteria-septic mice, while without providing additional effects on Casp11−/− mice, indicating PHZ-OH could specifically prevent caspase-11-dependent septic death (Fig. 2A, B). In view of the fact that interventions in clinics are commonly given after the onset of sepsis, we administered PHZ-OH after the operation of CLP or the injection of E. coli. Gratifyingly, similar results were found and could be afforded on caspase-11-dependent protection in the treatment of bacterial sepsis (Fig. S6).

To investigate whether PHZ-OH attenuates organ dysfunction in sepsis, the plasma levels of alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CREA) were determined, by which the dysfunction levels of the liver and the kidney are demonstrated. We found that CLP-augmented ALT, AST, BUN and CREA were significantly inhibited by the administration of PHZ-OH (Fig. 2C, D). Similarly, genetically deleting caspase-11 attenuated the organ dysfunction, and no further improvements were observed under PHZ-OH treatment of Casp11−/− mice (Fig. 2C, D). In addition, H&E staining confirmed that PHZ-OH significantly attenuated sepsis-induced lung injury, in line with the Casp11−/− mice group (Fig. 2E). Moreover, inhibition effects on the plasma levels of caspase-11-related IL-1α and IL-1β, but not TLR4-related TNFα and IL-6, were observed in PHZ-OH-treated mice, which are essentially consistent with the results of the Casp11−/− mice group (Fig. 2F, G). As indicated by western blot, PHZ-OH also dampened caspase-11-dependent GSDMD cleavage but not TLR4-regulated expression of caspase-11 (Fig. 2H). Thus, these results demonstrate that PHZ-OH significantly prevents sepsis-induced organ dysfunction and lethality by selectively inhibiting caspase-11 signaling.

Protective effects of PHZ-OH against sepsis do not rely on the inhibition of NLRP3 inflammasome
As PHZ-OH inhibits inflammasome-dependent IL-1β secretion from OMV- or E. coli-challenged macrophages (Fig. S5A), its effects on NLRP3 inflammasome should be identified. We thus treated peritoneal macrophages of WT and Nlpr3−/− deficient mice with LPS plus nigericin (NLRP3 inflammasome inducer) in the presence or absence of PHZ-OH. Interestingly, PHZ-OH demonstrated dose-dependent inhibition on NLRP3-induced cell death and IL-1β release, and 4 μM of PHZ-OH almost completely blocked the
canonical pyroptosis to a level as that of Nlrp3-deficient macrophages (Fig. 3A, B). To determine the effects of PHZ-OH and NLRP3 in in-vivo study, we subjected WT and Nlrp3−/− mice to CLP after administration of PHZ-OH or not, and it was discovered that CLP-induced mice death was not significantly altered by deleting NLRP3 alone but improved by an additional administration of PHZ-OH (Fig. 3C). In addition, similar trends were found in organ injury and dysfunction, in which sepsis-induced lung injury (Fig. 3D) and impaired function of the liver and the kidney (Fig. 3E, F) were attenuated under the administration of PHZ-OH rather than by deleting NLRP3. These results were phenocopied in similar experiments using Casp1−/− mice.
Fig. 1 A 1-hydroxy phenothiazinium-based small molecule inhibits OMV-mediated cytotoxicity and cytokine release in vitro. A Scheme showing the screening strategy to identify potent inhibitors of caspase-11 signaling; B Drug-like properties of PHZ-OH; C Cytotoxicity and IL-1α secretion of wild type (WT), Casp11−/−, Gsdmd−/−, or Nlrp3−/− mouse peritoneal macrophages under a treatment of PHZ-OH (5 μM), and/or a challenge of OMV (10 μg/mL) or E. coli (a MOI of 10) for 16 h; D Caspase-11 mRNA level and cytotoxicity of macrophages primed using LPS (1 μg/mL), Pam3cSK4 (1 μg/mL) or Poly(I:C) (1 μg/mL) for 3 h and challenged with OMV (10 μg/mL) or E. coli (a MOI of 10) for 16 h in the presence or absence of PHZ-OH (5 μM); E TLR4-dependent cytokines (TNFα and IL-6) released from WT or Casp11−/− macrophages under a treatment of saline or PHZ-OH (5 μM), and/or a challenge of OMV (10 μg/mL) for 16 h; F Western blots for IL-1α, IL-1β and caspase-11 expression and GSDMD cleavage in saline-treated or OMV-challenged macrophages under a treatment of saline or different doses of PHZ-OH (P, 5 or 10 μM); G–J LDH (G or I) and IL-1α as well as IL-1β (H or J) released from mouse peritoneal macrophages (WT and Casp11−/−) or THP-1 cells (Transfected with control or caspase-4 siRNA), respectively, in the presence of different concentrations of PHZ-OH (1, 2, 4 μM) and challenged with OMV (10 μg/mL) for 16 h. Data are shown as mean ± SEM of three independent experiments. *P < 0.05. ns, not significant.

Taken together, these results suggest that PHZ-OH protects against organ dysfunction and lethality in sepsis independent of NLRP3 inflammasome.

PHZ-OH protects against sepsis by inhibiting caspase-11 signaling in coordination of its antibacterial property

It is well-known that phenothiaziniums also possess outstanding antibacterial activities [20, 21], we thus examined the antibacterial effects of PHZ-OH against E. coli using standard activity assessment assay (Fig. 4A). The results showed that PHZ-OH demonstrated an excellent dose-dependent antibacterial effect (Fig. 4B). To identify whether the antibacterial property of PHZ-OH contributes to the protective effects towards bacterial sepsis, we determined the bacterial burden in the blood, the lung, and the spleen of mice challenged with CLP or E. coli. To our delight, PHZ-OH dampened the bacterial burden in the circulation and parenchymal organs in both models, including the liver, the lung, and the spleen (Fig. 4C, D). To further separate the effects of the antibacterial and anti-caspase-11 properties of PHZ-OH in the prevention of sepsis, we next subjected mice to a sterile endotoxemia model. Consistent with our aforementioned results (Fig. 2A, B), caspase-11 deletion nearly completely blocked LPS-induced mice death (Fig. 4E) and attenuated lung injury (Fig. 4F), further implicating the pivotal role of caspase-11 on the pathogenesis of gram-negative sepsis.

Moreover, administration of PHZ-OH significantly enhanced the survival rate of WT mice challenged with high dose of LPS (endotoxemia model), but it did not afford further improvement in Casp11−/− mice. These results thus suggest that PHZ-OH prevents gram-negative sepsis by inhibiting caspase-11 pathway in coordination of its intrinsic antibacterial property.

PHZ-OH protects mice via attenuating coagulation in gram-negative bacterial sepsis

We have previously revealed that caspase-11-dependent excessive coagulation activation would largely result in organ dysfunction and mortality in sepsis [22]. By using intravital microscopy, we herein visualized the microcirculation of hepatic sinusoid in intact and LPS-challenged mice. It was apparent that endotoxin (LPS) remarkably induced coagulation and subsequent vessel occlusion, and the administration of PHZ-OH significantly restored microcirculation to the level almost equivalent to that of Casp11−/− deficient mice (Fig. 5A, B). Besides, systematic coagulation activation dramatically augments the contents of thrombin-antithrombin (TAT) complex and plasminogen activator inhibitor type 1 (PAI-1), thereby consuming fibrinogen and increasing fibrinolysis and D-dimer, which are generally used as DIC markers [10, 22]. Almost in line with these illustrations, the plasma levels of TAT, PAI-1 and D-dimer, and the consumption of fibrinogen increased markedly in LPS-challenged mice when compared with the intact control (Fig. 5C, D). Notably, upon administration of PHZ-OH (5 mg/kg) to the mice under challenge of LPS, significant reductions of these DIC markers were observed in the WT mice, but not in Casp11−/− deficient mice (Fig. 5C, D). In addition, fibrin, the terminal executor of thrombosis in coagulation cascade, was determined by ELISA and immune-histochemical staining.

Consistently, the LPS-boosted fibrin deposition in the lung and the liver was largely alleviated by the treatment of PHZ-OH (Fig. 5E, F). Taken together, these results indicate that PHZ-OH prevents coagulation and attenuates organ injury in sepsis via blocking caspase-11 pathway, suggesting that PHZ-OH may serve as a promising therapeutic molecule for the treatment of gram-negative bacterial sepsis.

PHZ-OH suppresses LPS internalization and caspase-11-dependent TF activation

As it is known that the accessing of LPS stimulates the oligomerization and activation of caspase-11, we next determined the colocalization of LPS and caspase-11 by using Proximity Ligation Assay (PLA), with the aim to investigate the mechanism by which PHZ-OH inhibits caspase-11 signaling. The results clearly indicated that PHZ-OH dampened the accessing of LPS to caspase-11 upon OMV stimulation when using Casp11−/− deficient macrophages as the negative control (Fig. 6A, B). To reveal if the effects of PHZ-OH involve LPS internalization, we directly delivered LPS into the cytosol of mouse macrophages by electroporation. Of note, PHZ-OH failed to inhibit the caspase-11-dependent cell death (Fig. 6C) and the release of IL-1α/β (Fig. 6D). Alternatively, it suppressed the OMV-mediated cytotoxic level of LPS (Fig. 6E, F), suggesting that PHZ-OH inhibits caspase-11 pathway by blocking the cytosolic internalization of LPS rather than other signals. In addition, we have previously found that caspase-11-mediated pore-forming induces phosphatidyserine exposure, thus boosting tissue factor (TF) activity and triggering the extrinsic coagulation cascade that eventually mediates thrombin formation [6]. Consistent with our previous findings, PHZ-OH in the present study lowered down OMV-augmented TF activity as well as the formation of OMV-inflicted thrombin (Fig. 6G, H). Collectively, PHZ-OH suppresses LPS internalization and thus prevents coagulation in sepsis by inhibiting caspase-11-boosted TF activity and the formation of thrombin.

PHZ-OH inhibits LPS internalization by blocking AAK1-mediated endocytosis

It is well-documented that clathrin-dependent endocytosis functions in OMV-induced cytotoxic LPS delivery [12]. To investigate the target of PHZ-OH in the inhibition of LPS internalization, we determined the binding of PHZ-OH with potential proteins involving LPS or clathrin-dependent endocytosis by using molecular docking, a computational approach for predicting the binding energy between the target and the ligands [23] (Fig. 7A and Table S2). We found that AP2-associated protein kinase 1 (AAK1), a key regulator of AP2 in clathrin-dependent endocytosis, showed highest binding energy (~8.7 kcal/mol) with PHZ-OH (Fig. 7A, B). In order to validate the physical binding of PHZ-OH and AAK1, we conducted surface plasmon resonance (SPR) [24] and discovered a high affinity between PHZ-OH and AAK1 (KD = 4.67 × 10−6 M, Fig. 7C). Furthermore, we verified that AAK1 knockdown (Fig. 5A) significantly inhibited OMV-augmented cytotoxic LPS, whilst additional intervention of PHZ-OH onto AAK1-silenced macrophages did not display further...
effects (Fig. 7D), which was phenocopied in the levels of OMV-mediated cytotoxicity and IL-1α/β release (Fig. 7E). Given that macrophage scavenger receptor 1 (Msr1) mediates LPS internalization as shown in our previous study [22], we assessed the relationship of Msr1 and AAK1 in OMV-induced caspase-11 activation. It was observed that either administrating PHZ-OH or silencing AAK1 did not further decline OMV-augmented intracellular LPS and release of LDH and IL-1α/β on the basis of deleting Msr1 (Fig. 7D, E), indicating that Msr1 mediates cytosolic translocation of LPS via AAK1 signaling. As it is known that OMV...
delivers LPS into the cytosol via early endosome [12], we next knocked down Rab5 (Fig. S8B), an essential regulator of early endosome, in WT or Msr1-deficient macrophages. The results showed that knockdown of Rab5 significantly inhibited OMV-induced pyroptosis (Fig. 7F), almost in consistent with the reported findings [12]. Besides, similar to knockdown of AAK1, silence of Rab5 did not show additional effects on Msr1-deficient cells and PHZ-OH did not further affect Rab5-silenced cells in terms of OMV-induced cell death and cytokine release, implying Msr1-mediated endocytosis is involved in the process. Given that endosomal LPS accesses the cytosol under the assistance of guanylate-binding proteins (GBPs) [25], we conducted a similar experiment using WT or Gbp2-deficient cells (Fig. 7G). It was observed that GBP2 deletion, AAK1 knockdown and PHZ-OH administration alone had significant inhibition but did not display synergistic effects on OMV-induced pyroptosis (Fig. 7G). Taken together, these results indicate that Msr1/AAK1-dependent endocytosis is a pivotal signaling for regulating OMV-mediated cytosolic delivery of LPS and caspase-11 activation, and PHZ-OH is able to inhibit the LPS endocytosis via targeting AAK1.

**PHZ-OH attenuates endotoxin-induced coagulation and lethality by inhibiting AAK1**

To investigate the inhibitory effect of PHZ-OH on AAK1 in in vivo study, we treated LPS-challenged mice with PHZ-OH and/or AAK1-IN-1 (a well-known AAK1 inhibitor). Either PHZ-OH or AAK1-IN-1 alone significantly improved the survival rate of mice and reduced caspase-11-related cytokines in endotoxemia model, whilst PHZ-OH plus AAK1-IN-1 did not display any additional improvement and reduction, respectively (Fig. 8A, B). Moreover, LPS-inflated coagulation levels, such as increase of PAI-1, TAT and D-dimer, consumption of fibrinogen, and augment of fibrin in the lung and the liver, were significantly dropped when administrating PHZ-OH or AAK1-IN-1 (Fig. 8C–E). Nevertheless, PHZ-OH and AAK1-IN-1 did not have synergistic effects on the inhibition of coagulation (Fig. 8C–E). Further in vivo study using Msr1−/− mice also indicated that administration of PHZ-OH did not significantly affect LPS-induced mortality and augment of IL-1α/β and coagulation at the basis of Msr1 depletion (Fig. 8F, G). These results thus suggest that Msr1/AAK1 is essential for endotoxin-induced coagulation and death, and PHZ-OH can suppress the complications through targeting AAK1.

**DISCUSSION**

Caspase-11, as an intracellular LPS sensor of innate immune system, is not only able to mediate GSDMD-dependent cell death, but also can trigger NLRP3 inflammasome, thereby inducing the release of inflammatory cytokines independent or dependent of the inflammasome [18]. Our previous study has revealed the
essential role of NLRP3 inflammasome for clearing invading pathogens in moderate infection [26]. Nevertheless, caspase-11 is reported to be different from caspase-1 in the defense of infection [27]. In addition, overactivation of caspase-11, commonly caused by severe bacterial infection, can induce organ dysfunction and host death in sepsis [3–5]. We have previously found that blocking caspase-11 genetically and pharmacologically significantly reduces sepsis-induced organ injury and lethality, and thus may be a promising strategy for the treatment of sepsis [6, 28]. Consistently, PHZ-OH, a novel 1-hydroxy phenothiazinium-based small molecule identified in this study, significantly prevents coagulation, organ dysfunction and death in sepsis by inhibiting caspase-11 signaling rather than NLRP3 inflammasome. Furthermore, the inhibition effect of PHZ-OH does not affect global inflammation, including the release of TNFα and IL-6. The selective inhibition may allow the maintenance of host response to secondary infection and avoid immunosuppression. Although inflammatory cytokine storm is commonly accompanied by organ injury or even death in sepsis, targeting inflammation therapy remains questionable in clinical applications [29, 30]. It has been proved that anti-TNFα antibody or antagonists of TLR4 fails to decline the mortality of septic patients [31–33]. Thus, PHZ-OH, with selectively blocking caspase-11 signaling but not the global inflammation, would be an alternative and favorable medicine candidate for rescuing sepsis.

We recently bridged caspase-11 and coagulation activation independent of inflammatory response [6]. In the present study, PHZ-OH demonstrates the ability to prevent coagulation by inhibiting caspase-11 signaling. Given that overactivation of coagulation and the emergence of DIC would be the major cause
of organ injury and death in sepsis [2, 8, 9], anticoagulation therapeutics were previously brought into clinical trials for treating septic patients with DIC. However, administration of anticoagulant agents displays a risk of bleeding and fails to improve the prognosis of patients with sepsis [2, 34, 35]. In the present study, PHZ-OH blocks the key pathway that initiates the blood coagulation cascade but not the cascade itself. This strategy may provide an alternative option to rescue coagulation syndrome and improve the prognosis of sepsis.

Mechanistically, we discovered that Msr1/AAK1-dependent endocytosis essentially functions in OMV-mediated LPS internalization. Internalization of LPS by endocytosis is firstly required for caspase-11 activation in the sensing process [12]. AAK1 recruits AP2 to the cell membrane and phosphorylates the threonine residue of the μ-subunit (AP2M1), which enhances the binding of AP2 with cargo and increases clathrin-dependent endocytosis [36]. PHZ-OH inhibits AAK1-mediated LPS internalization and leaves the function of caspase-11 intact, which does not affect the physiological function of caspase-11 in the protection against cytosolic bacteria and the surveillance of immune cells [37]. Thus, the selective inhibition effect of PHZ-OH on caspase-11 signaling may have fewer side effects, and inhibition of LPS internalization by targeting AAK1 would be a promising strategy in the treatment of bacterial sepsis. In addition, a recent study suggested that baricitinib, approved for treating

**Fig. 5** PHZ-OH inhibits coagulation and attenuates organ injury in mice challenged with LPS. WT or Casp11−/− mice were primed with LPS (0.4 mg/kg) for 7 h prior to an intervention of PHZ-OH (5 mg/kg) and/or a challenge of LPS (4 mg/kg for 6 h for SD-IVM images or 10 mg/kg for 12 h for coagulation markers). A Representative SD-IVM images showing the circulating blood (Red) and the occlusion (as indicated by arrows) of the liver microvasculature that was clued by the signal of circulating blood (Red) and the autofluorescence of hepatocytes (Green); B Percent occluded region of the microvasculature related to the imaging field; Plasma concentrations of PAI-1 and TAT (C), and Fibrinogen and D-dimer (D); E Fibrin concentrations in the lung and the liver; F IHC staining showing the fibrin deposition in the lung (Dark brown, as indicated by arrows). Data are mean ± SEM of three mice for (B) and six mice for (C–E) in one experiment. *P < 0.05. ns, not significant. Scale bar = 50 μm.
rheumatoid arthritis, may serve as an anti-SARS-CoV-2 drug by inhibiting AAK1-regulated virus endocytosis. Thus, AAK1 would be a hopeful anti-SARS-CoV-2 target and PHZ-OH may be a new potential candidate for drug development to treat SARS-CoV-2, which remains to be investigated in further study.

In addition to the inhibition effect on caspase-11-mediated coagulation, PHZ-OH also demonstrates excellent dose-dependent antibacterial activity, which may further improve therapeutic effects for the treatment of sepsis, especially in the current era of rapid emergence of multi-drug-resistant bacteria. Taken
together, our study for the first time discovered a novel 1-hydroxy phenothiazinium-based molecule (PHZ-OH), capable of preventing bacterial sepsis by selectively inhibiting AAK1-mediated LPS internalization for caspase-11 activation, which may provide a novel target and a potent therapeutic molecule in the treatment of bacterial sepsis.

METHODS AND MATERIALS
Reagents
General chemical reagents were purchased from commercial suppliers (Acros/Aldrich Chemical Co. Ltd, USA, J & K Scientific Ltd, China) and used without further purification, unless otherwise noted. LDH Assay kits were from Beyotime Biotechnology (Cat: C0017). Commercial ELISA kits
including mouse IL-1α (Cat: 88-5019, Invitrogen), mouse IL-1β (Cat: 88-7013, Invitrogen), mouse TNF (Cat: 88-7324, Invitrogen), mouse IL-6 (Cat: 88-7064, Invitrogen) human IL-1α (DY200, R&D), human IL-1β (Cat: 88-7261, Invitrogen), mouse D-dimer (Cat: CEA506Mu, Cloud-Clone), mouse fibrinogen (Cat: ab108844, Abcam), mouse PAI-1 (Cat: ab197799, Abcam) and mouse fibrin (MBS164817, MybioSource) were purchased from commercial suppliers as indicated.

**Fig. 7** PHZ-OH inhibits LPS internalization by blocking AAK1-mediated endocytosis. A Binding energy of PHZ-OH with potential targets determined by using molecular docking [23]; B The computational 3D binding model between PHZ-OH and AP2-associated protein kinase 1 (AAK1); C The RU (response unit) vs. time in a sensorgram showing PHZ-OH (2.5, 5, 10, 20 and 40 μM) binding to the chip-immobilized AAK1 after subtracting the control signal (KD = 4.67 × 10^{-6} M); D LPS level of the cytosolic fraction assessed by using LAL assay in WT, AAK1-silenced, or Msr1-deficient macrophages challenged with OMV (10 μg/mL) for 2 h in the presence or absence of PHZ-OH (4 μM); E Cytotoxicity and IL-1α/β release of WT, AAK1-silenced, or Msr1-deficient macrophages treated with saline or OMV (10 μg/mL) for 16 h in the presence or absence of PHZ-OH (4 μM); F Cytotoxicity and IL-1α/β release of WT, Rab5-silenced, or Msr1-deficient macrophages treated with saline or OMV (10 μg/mL) for 16 h in the presence or absence of PHZ-OH (4 μM); G Cytotoxicity and IL-1α/β release of WT, AAK1-silenced, or Gbp2-deficient macrophages treated with saline or OMV (10 μg/mL) for 16 h in the presence or absence of PHZ-OH (4 μM). Data are shown as mean ± SEM of three independent experiments. *P < 0.05. ns, not significant.

**Fig. 8** PHZ-OH alleviates endotoxin-induced coagulation and lethality by inhibiting AAK1. A Survival rate of WT mice treated with PHZ-OH (5 mg/kg) and/or AAK1-IN-1 (5 mg/kg) prior to a challenge of LPS (25 mg/kg); Plasma levels of IL-1α/β (B), PAI-1 and TAT (C), and fibrinogen and D-dimer (D), and fibrin concentrations of the lung and the liver (E) in WT mice primed with LPS (0.4 mg/kg) for 7 h prior to an intervention of PHZ-OH (5 mg/kg) and/or a challenge of LPS (10 mg/kg) for 12 h. F Survival rate of WT and Msr1−/− mice treated with or without PHZ-OH (5 mg/kg) prior to a challenge of LPS (25 mg/kg); G Plasma IL-1α/β levels of saline-treated or LPS-challenged (0.4 mg/kg LPS for 7 h and a following 10 mg/kg LPS for 12 h) WT and Msr1−/− mice under an intervention of PHZ-OH (5 mg/kg) or not. Data are mean ± SEM of six mice in one experiment. *P < 0.05. ns, not significant.
SensoLyte internally quenched 5-FAM/QXL-520 FRET thrombin substrate (Cat: AS-72129, AnaSpec) were obtained to detect TF activity and thrombin formation, respectively. Antibodies used in this study, including anti-caspase-11 (Cat: C1354, Sigma), anti-mouse GSDMD (Cat: ab209845, Abcam), anti-mouse IL-1α (Cat: ab7632, Abcam), anti-mouse IL-1β (Cat: AF-401-NA, R&D system) and anti-mouse β-actin (clone 8H11D10, Cat: 37005, Cell Signaling Technologies), were commercially obtained except an anti-mouse fibrin antibody (59D8)—a gift from Prof. Nickel Mackman. AAK-1N-1 (E0498) was purchased from Selleck, and siRNAs were ordered from Ribobio. Nigericin (tiril-nig-5) and Ultra-LPS (tirlb5lps) were purchased from InvivoGen, whilst LPS derived from E. coli 0111:B4 was from Sigma (L2630). OMV was collected and purified as previously described [12]. In brief, E. coli (ATCC 25922) was cultured in 5 x 200 mL of LB at 37 °C and 220 rpm until OD600 of 0.5 was achieved. Supernatant was harvested after a centrifuge at 10,000 g for 10 min at 4 °C followed by a filtration through a 0.45 μm filter to remove bacteria and debris. OMVs were then isolated by ultracentrifugation at 400,000 × g for 1.5 h at 4 °C in a Beckman optima L-100 XP rotor and resuspended in 1.5 mL of sterile ultrapure PBS. The protein level was assessed by using Pierce BCA protein assay kit (Thermo Scientific) and a final filtration was conducted via a 0.45 μm filter before further applications.

Mice and models of endotoxemia and bacterial sepsis

Casp11−/− (Jackson Laboratory, 024698), Casp11+/− (Jackson Laboratory, 032662), Casp11+/−/− (Jackson Laboratory, 016621), Nrfl3−/−/− mice (Jackson Laboratory, 021302), HCV mice (express human tissue factor, Nickel Mackman Lab), Mdy88−/− (Jackson Laboratory, 030908), Gbp2−/− (GmpPharmatech Co., Ltd, T028952), Mr1−/− (GmpPharmatech Co., Ltd, T014930) and WT male C57BL/6J mice, with age of 8–10 weeks and body weight of 22–25 g, were used randomly from a breeding colony without blinding. Mice were treated with saline or chemicals for 30 min before or after a challenge of cecal ligation and puncture (CLP), 104 CFU E. coli (ATCC, 25922) or 25 mg/kg LPS. Survival rates (around 10 mice per group) were observed for 7 days, whilst the tissues or the plasma were obtained at 12 h after challenges (6 mice per group). To generate DIC-like model (6 mice per group), mice were primed with 0.4 mg/kg LPS for 7 h and challenged with 10 mg/kg LPS [3, 4, 6]. Chemicals were intraperitoneally injected 30 min prior to the challenge of 10 mg/kg LPS. In order to visualize most of the microvascular that are not completely occluded under intravital microscopy (3 mice per group), 4 mg/kg of LPS after priming were intraperitoneally injected to mice 6 h prior to imaging [6, 10]. Standard condition at room temperature and a 12-h light-dark cycle were provided to all mice that were free to access to water and standard chow. Animal experiments were carried out in compliance with the guidelines by the committee of Xiangya Hospital and Central South University.

Cecal ligation and puncture (CLP)

After anesthetized with 2% isoflurane (Piramal Critical Care) in oxygen, mice were subjected to a 1.5 cm longitudinal midline incision. The cecum was exposed and ligated (75%) prior to a through-and-through puncture of the cecum and a close of the abdomen. Recovery was allowed by injecting prewarmed saline (1 mL per mouse) in a 37 °C warmer. Sham-operated mice were subjected to the same surgery except the ligation and the puncture.

Intravital microscopy and image analysis

To real-time visualize the circulation of microvasculature, the left liver of mice was exposed and externalized on a thin glass coverslip after animal were anesthetized with xylazine hydrochloride (10 mg/kg) and ketamine hydrochloride (20 mg/kg). The glass coverslip was then loaded on the thermal control stage of the inverted microscope of the confocal intravital microscopy, followed by injecting AF647-conjugated anti-mouse albumin antibody (0.05 μg/mouse) via the right jugular vein. Fluorescent images were acquired and the analysis was conducted as previously described [6, 10].

Cell culture

As previously described [6, 10], mouse peritoneal macrophages were obtained and purified from Casp11−/−, HCV (human TF positive), Mr1−/− or WT C57BL/6J male mice. The cells were plated overnight prior to the treatment of siRNA (Ribobio, China) or chemicals (1–10 μM) and then the challenge of OMV (10 μg/mL). In addition, THP-1 cells were plated and treated with 20 ng/mL of PMA (Sigma) overnight. Interventions of chemicals (1–4 μM) were given when the cells were challenged with OMV (10 μg/mL).
factor X) at 37 °C for 30 min, followed by addition of Factor Xa substrate. The absorbance at 405 nm was determined and the TF activity was calculated according to the standard absorbance curve. Thrombin generation assay was used to assess thrombin formation [6]. Briefly, the mixture containing 10 μL cell supernantant and diluted platelet poor plasma was subjected to 50 μL thrombin substrate. The fluorescence intensity was detected by using TECAN multi-functional fluorescence microplate reader.

**Molecular docking and surface plasmon resonance**

Molecular docking is a computational approach to calculate the binding energy between proteins and ligands [23], were used for screening the target of PHZ-OH. Given that OMV mediates cytotoxic delivery of LPS by clathrin-dependent endocytosis [12], the crystal structures of potential targets, including LPS-related receptors or endocytosis-associated proteins, were retrieved from http://www.rcsb.org/ (Table S2), while the structural properties that influence the oral bioavailability of drug candidates. J Med Chem. 2020:63:4896–907.

Yang X, Cheng X, Tang Y, Zhao X, Cheng X, Zhong R, Zhang X, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49:740–53e747.

Phoenix DA, Harris F. Phenothiazinium-based photosensitizers: antibacterials of the future? Trends Mol Med. 2003:9:283–5.

Xiao Q, Ma B, Nie Y, Yuan C, Xiang M, Shi Z, et al. In vitro and in vivo demonstration of ultraefficient and broad-spectrum antibacterial agents for photodynamic anti-bacterial chemotherapy. ACS Appl Mater Interfaces. 2021:13: 11588–96.

Yuan C, Wu M, Xiao Q, Zhao W, Li H, Zhong Y, et al. Blocking Msr1 by berberine alkaldoids inhibits caspase-11-dependent coagulation in bacterial sepsis. Signal Transduct Ther. 2021:6:92.

Sampatik P, Mujumdar P, Taylor P, Cross M, Coster MJ, Gorse AD, et al. Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery. Biotechnol Adv. 2015:33:941–7.

Acimović SS, Ortega MA, Sanz V, Berthollet J, Garcia-Cordero JL, Renger J, et al. LSFR chip for parallel, rapid, and sensitive detection of cancer markers in serum. Nano Lett. 2014:14:2636–41.

Finethy R, Luoma S, Orench-Rivera N, Feeley EM, Haldar AK, Yamamoto M, et al. Inflammamson activation by bacterial outer membrane vesicles requires gua-nylate binding proteins. mBio. 2017;8:e01188–17.

Zhong Y, Lu Y, Yang X, Tang Y, Zhao K, Yuan C, et al. The roles of NLRP3 in bacterial infection. Mol Immunol. 2020:122:80–8.

Broz P, Ruby T, Belohcine K, Bouley DM, Kayagaki N, Dixit VM, et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature. 2012:490:288–91.

Yan X, Cheng X, Tang Y, Qu X, Wang Y, Kang H, et al. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphati-dyserine exposure. Immunity. 2019;51:983–96986.

Engelmann B, Massberg S. Thrombosis as an intra-vascular effector of innate immunity. Nat Rev Immunol. 2013:13:34–45.

Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thrombosis Haemost. 1980;43:28–33.

Levi M, Ten Cate H. Disseminated intravascular coagulation. J Thrombosis Haemost. 2006;4:90–7.

Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885–91.

Deng M, Scott MJ, Loughran P, Gibson G, Soodi C, Watkins S, et al. Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol. 2013:190:5152–60.

Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORA3ST II Group Study. Lancet. 1998;351:929–33.

Opat SM, Laterre PF, Francois B, LaRossa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013:309:1154–62.

Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Alkawa N, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38:1685–94.

Warren BL, Eld A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose anti thrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–78.

Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose anti thrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thrombosis Haemost. 2006;4:90–97.

Ricotta D, Conner SD, Schmid SL, von Figura K, Honying S. Phosphorylation of the AP2 mu subunit by AK1 mediates high affinity binding to membrane protein sorting signals. J Cell Biol. 2002;156:791–5.

Achoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE, et al. Caspase-11 protects against bacteria that escape the vacuole. Science. 2013:339:975–8.
ACKNOWLEDGEMENTS
The authors thank Prof. Nigel Mackman for sharing HCV mice and anti-fibrin antibody, and Dr. Bin Yu (ZZU) for helpful discussion in the study.

AUTHOR CONTRIBUTIONS
CY and KLA performed the majority of the experiments and wrote the manuscript. QCX designed and synthesized the new compounds, and MHX and CLX helped to characterize the compounds. XMP, HL, MYZ, and MW analyzed the in vitro data and constituted the figures. HLL, YRW, YJZ, and YQC helped to handle the in vitro study and mice breeding. LQG helped to supervise and validate the study. XYY and QCX designed the project, supervised, and contributed in reviewing and finalizing the manuscript.

FUNDING
This study was supported by National Natural Science Foundation of China (82072152, 21877130, and U1801681), Natural Science Foundation of Hunan Province (2022J30793), Hunan Natural Science Fund for Distinguished Young Scholars (2021JJ10072), Natural Science Fund of Guangdong Province (2021A1515010357, 2018A030313600), Shenzhen Science and Technology Program (JCYJ20210324124411032), and Science and Technology Program of Guangzhou (201803010009).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
Animal experiments and protocols were approved by the Institutional Animal Care and Use Committees of Central South University.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-05151-7.

Correspondence and requests for materials should be addressed to Qicai Xiao or Xinyu Yang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.